Legit Tirzepatide

Tirzepatide Dosage: The Clinical Trial and FDA-Label Evidence | Tirzepatide

The short version

Tirzepatide dosage in the clinical programme follows a stepwise escalation from a low starting dose to a maintenance dose. The FDA prescribing information documents a 2.5 mg subcutaneous injection once weekly as the initiation dose, escalated by 2.5 mg every four weeks, with maintenance doses of 5 mg, 10 mg, or 15 mg once weekly. That escalation schedule exists to manage gastrointestinal side effects — nausea and other GI symptoms are most common during dose increases. The half-life of approximately 5 days supports the once-weekly dosing schedule. The only route studied in the approved programme is subcutaneous injection. This page reads what the FDA label and the SURPASS/SURMOUNT trials documented about tirzepatide dosage — it is a clinical record, not a personal recommendation.

Tirzepatide dosage: the FDA-label titration schedule

The FDA-approved prescribing information for tirzepatide documents the following dosing framework for type 2 diabetes and chronic weight management indications [6]:

  • Initiation: 2.5 mg subcutaneous once weekly for four weeks (not a therapeutic dose — a tolerability initiation dose)
  • Escalation: Increase by 2.5 mg every four weeks
  • Maintenance doses studied: 5 mg, 10 mg, and 15 mg once weekly (the three doses evaluated in the SURPASS and SURMOUNT phase 3 trials)
  • Maximum dose: 15 mg once weekly

The full escalation ladder from initiation to maximum maintenance: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, with four weeks at each step.

The prescribing information notes that if a dose increase is not tolerated, reduction to the previous dose level can be considered temporarily. The 5 mg dose is the lowest maintenance dose studied across the major phase 3 trials; the 2.5 mg initiation dose was not used as a maintenance comparator in the efficacy trials.

This titration schedule is a label-documented clinical framework. It is not a personal recommendation, and prescribing decisions rest with a licensed physician.

Tirzepatide dose: trial-level maintenance doses and outcomes

The three maintenance doses — 5 mg, 10 mg, and 15 mg — produce a clear dose-response gradient across the major efficacy trials.

In SURPASS-2 (type 2 diabetes, n=1,879, 40 weeks) [2]:

  • 5 mg: HbA1c -2.01 pp; weight -7.6 kg
  • 10 mg: HbA1c -2.24 pp; weight -9.3 kg
  • 15 mg: HbA1c -2.30 pp; weight -11.2 kg
  • Semaglutide 1 mg (comparator): HbA1c -1.86 pp; weight -5.7 kg

In SURMOUNT-1 (obesity without diabetes, n=2,539, 72 weeks) [3]:

  • 5 mg: weight -15.0%
  • 10 mg: weight -19.5%
  • 15 mg: weight -20.9%
  • Placebo: weight -3.1%

In SURMOUNT-5 (obesity without diabetes, head-to-head, maximum tolerated doses, n=751, 72 weeks) [4]:

  • Tirzepatide maximum tolerated dose (10 or 15 mg): weight -20.2%
  • Semaglutide maximum tolerated dose (1.7 or 2.4 mg): weight -13.7%

The dose-response is consistent and monotonic across both the diabetes and obesity programmes. The 15 mg dose consistently produces the largest reductions and is the dose most commonly reaching weight-loss thresholds of ≥20% and ≥25%.

Tirzepatide injection: route, pharmacokinetics, and half-life

Tirzepatide injection route: Subcutaneous injection is the only route used in the approved programme and FDA-approved indications [6]. In the SURPASS and SURMOUNT trials, injections were administered in the abdomen, thigh, or upper arm, rotating sites. An autoinjector pen format was used in the pivotal trials.

Pharmacokinetics: The approximately five-day half-life is conferred by the C20 fatty-diacid arm attached to the peptide backbone. This modification produces high albumin affinity, dramatically slowing clearance and enabling once-weekly dosing from a molecule that would otherwise be rapidly degraded. Phase 1 work established PK parameters supporting the once-weekly schedule [1].

The long half-life has one clinically relevant consequence: delayed gastric emptying transiently induced by tirzepatide has a roughly five-day window of significant pharmacological activity. This is a consideration for procedures requiring an empty stomach — the gastric-emptying effect and drug clearance timelines overlap [24].

Stability: Approved formulations are refrigerated. Specific storage parameters are formulation-specific and are documented in the prescribing information rather than the efficacy literature.

Tirzepatide dose in older adults: A post hoc analysis of pooled SURPASS-1 to -5 data in adults ≥65 years without obesity found that tirzepatide reduced HbA1c by -1.97% to -2.10% across doses in this subgroup. Weight reduction was dose-proportional but numerically lower than the overall cohort. Hypoglycaemia incidence was consistent with the overall cohort regardless of concurrent insulin or sulfonylurea use [33].

What the dose data do not tell us

Three questions remain open in the dosage literature.

First, optimal duration of the escalation phase: the approved four-week-per-step schedule is what the trials used, but some patients tolerate escalation faster and some slower. Whether alternative escalation speeds affect the GI tolerability-efficacy trade-off has not been evaluated in a dedicated trial.

Second, long-term maintenance at lower doses: the major efficacy trials ran 40–72 weeks at fixed maintenance doses. Whether a lower maintenance dose after initial weight or glycaemic goals are achieved produces different durability outcomes than the dose used for induction has not been tested.

Third, injection site preference: the approved sites (abdomen, thigh, upper arm) were used interchangeably in the trials without pharmacokinetic differentiation between sites. Site-specific absorption differences have not been characterised in the tirzepatide programme specifically, though they are a known variable in subcutaneous drug delivery generally.

For the broader evidence record on what tirzepatide research has established — mechanism, outcomes, and the cardiometabolic expansion — see the Tirzepatide research page.